Brain mononuclear phagocyte (MP; macrophage and microglia) activation and neuronal injury are central features of HIV-1 encephalitis (HIVE), the pathological correlate of HIV-1-associated dementia (HAD). However, the pathways through which brain MP activation occurs and elicits neuronal dysfunction remains poorly understood. Recently, others and we demonstrated that neural injury can directly affect MP activation, through production of neuronal chemokines such as fractalkine (FKN). FKN is constitutively expressed on neurons and can be released in a soluble form. FKN can activate MP and induce cytokine secretion. Further, CSF levels of FKN are higher in HAD patients than in infected subjects without neurological disease. Thus, we hypothesize that MP recruitment and activation in HAD is regulated, in part, by FKN. While it is acknowledged that MP secrete both neurotrophic and toxic factors following viral infection and activation, the signaling pathways which selectively regulate these processes remain to be elucidated. To this end, we propose that FKN-stimulation and HIV-1 infection of brain MP leads to the activation of multiple protein kinase pathways, such as the MAP kinases. Activation of these pathways result in neurotrophic and toxic factor dysregulation and ultimately neuronal compromise. Primary human macrophage, microglia and neuronal culture systems, combined with """"""""state-of-the-art"""""""" human gene microarray technology, will be used to study how FKN mediates MP activation, affects intracellular signaling pathways, and regulates both neurotrophic and neurotoxic factor production. The determination of mechanisms involved in FKN-mediated MP activation and secretory factor production may assist in identification of potential targets for therapeutic intervention. This project unites with others in the program in seeking to determine how MP immunity affects the neurodegenerative process associated with HAD.
| Olson, Katherine E; Bade, Aditya N; Namminga, Krista L et al. (2018) Persistent EcoHIV infection induces nigral degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. J Neurovirol 24:398-410 |
| Schutt, Charles R; Gendelman, Howard E; Mosley, R Lee (2018) Tolerogenic bone marrow-derived dendritic cells induce neuroprotective regulatory T cells in a model of Parkinson's disease. Mol Neurodegener 13:26 |
| Thomas, Midhun B; Gnanadhas, Divya Prakash; Dash, Prasanta K et al. (2018) Modulating cellular autophagy for controlled antiretroviral drug release. Nanomedicine (Lond) 13:2139-2154 |
| Kiyota, Tomomi; Machhi, Jatin; Lu, Yaman et al. (2018) URMC-099 facilitates amyloid-? clearance in a murine model of Alzheimer's disease. J Neuroinflammation 15:137 |
| Kevadiya, Bhavesh D; Woldstad, Christopher; Ottemann, Brendan M et al. (2018) Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution. Theranostics 8:256-276 |
| McMillan, JoEllyn; Szlachetka, Adam; Slack, Lara et al. (2018) Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. Antimicrob Agents Chemother 62: |
| Sillman, Brady; Woldstad, Christopher; Mcmillan, Joellyn et al. (2018) Neuropathogenesis of human immunodeficiency virus infection. Handb Clin Neurol 152:21-40 |
| Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65 |
| Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev : |
| Zhou, Tian; Lin, Zhiyi; Puligujja, Pavan et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond) 13:871-885 |
Showing the most recent 10 out of 240 publications
